Once again, we have a report of a ‘new’ treatment for pancreatic cancer. In case you didn’t know, pancreatic cancer is reported to be one of the most deadly cancers that one can contract. It is very difficult to diagnose in the early stages because there are no symptoms, and even when they do appear, they are often mistaken for other health problems. To date, there appears to be no reliable diagnostic test to detect it early. It is claimed that the cause of pancreatic cancer is unknown, but the authorities do readily admit that only a small percentage of cases are the result of heredity. They say that it is rare to catch pancreatic cancer in the early stages.
After reviewing an article on this ‘new’ treatment for pancreatic cancer, I couldn’t help analyzing it. In short, this ‘new’ treatment utilizes a ‘pancreatic cancer-specific radio-labeled antibody combined with low-dose gemcitabine chemotherapy’. In plain English, this means that an antibody that has an affinity for pancreatic cancer has a radioactive nuclide chemically attached to it. The antibody then has a higher tendency to attach to the pancreatic cancer cells, and kill them with the radioactivity. To enhance the effect, the gemcitabine is given in a ‘low-dose’ chemotherapy treatment. continue reading…
